文献速递生殖医学

性腺毒性治疗前的精子冷冻保存:单一学术中心40年经验

Sperm cryopreservation prior to gonadotoxic treatment: experience of a single academic centre over 4 decades.
PubMed 文献 · Hum Reprod · 2019-01-01

澳大利亚一家三级学术中心1978年至2017年的回顾性研究,纳入2717名男性,其中癌症患者2085名、非癌疾病患者234名、健康对照398名。几乎所有面临性腺毒性治疗的男性均可冻存精子,但精子处置时机因原因而异;偏远地区居民冻存比例仅约为城市居民的一半。

要点

  • 癌症与非癌疾病患者的精子输出均低于对照。
  • 全部冻存样本的中位冻存时间为8.5年,7%被转移用于诱导妊娠。
  • 62.2%因不再需要而被丢弃,其中生育力恢复者35.9%、死亡者26.3%。

核心结论

  • 精子冷冻保存在几乎所有面临性腺毒性治疗的男性中可行,包括能够采集精液的足够成熟青少年;定期随访下不再需要时处置冻存材料是高效的。
  • 作者认为精子冷冻保存应成为接受性腺毒性治疗男性综合治疗计划的组成部分,但目前仍未得到充分利用。

研究设计与样本

  • 回顾性研究,分析1978年至2017年单一三级学术中心的临床、人体测量、精液分析和激素数据。
  • 共纳入2717名男性,包括癌症患者2085名、非癌疾病患者234名、健康对照398名;同一诊所和实验室人员。

主要发现

  • 2085名癌症患者中,血液系统恶性肿瘤904名(43%)、睾丸癌680名(33%)、青少年136名(6.5%)。
  • 多数男性和青少年能够采集精子,分别为89%和80%。
  • 所有癌症和非癌疾病的精子输出均低于对照。
  • 精子输出与总睾丸体积正相关(r=0.44,P<0.0001),与血清FSH和LH负相关(r分别为-0.24、-0.12,均P<0.0001),与睾酮不相关。
  • 全部冻存样本中位冻存时间8.5年,7%被转移用于诱导妊娠(中位时间2.5年);62.2%因不再需要而丢弃(生育力恢复35.9%,中位3.5年;死亡26.3%,中位6.5年)。

关键数值与推荐

  • 偏远和农村地区无冷冻保存设施,外区域和偏远地区居民冻存精子的比例仅约为城市居民的一半。
  • 高丢弃率反映每年定期随访以确定是否仍需继续冻存。

临床怎么用

  • 作者认为精子冷冻保存应成为接受性腺毒性治疗男性综合治疗计划的组成部分,但目前仍未得到充分利用;原文未据此给出其他临床推荐。

局限性

  • 本研究未报告使用冻存精子患者的妊娠结局,原因是近期健康数据隐私方面的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the natural history of outcomes of sperm cryostorage at an Australian tertiary academic centre? SUMMARY ANSWER: Cryostorage is feasible in virtually all men facing gonadotoxic therapy but the timing of sperm disposal varies according to the reason for it. WHAT IS KNOWN ALREADY: Gonadotoxic treatment for cancer or non-cancer diseases damages spermatogenesis and impairs male fertility. Sperm cryopreservation is an established technique to preserve male fertility prior to gonadotoxic treatment. STUDY DESIGN, SIZE, DURATION: A retrospective review of clinical, anthropometric, semen analysis and hormonal data from 1978 to 2017 involving 2717 men comprising 2085 men with cancer, 234 non-cancer disease and 398 healthy controls, in a single tertiary academic centre with the same clinic and laboratory staff. PARTICIPANTS/MATERIALS, SETTING AND METHODS: Sperm output was analysed according to diseases, the feasibility of sperm cryostorage notably for adolescents, regional access to an urban cryostorage facility, the determinants of sperm output and time-dependent disposal of cryostored sperm. Semen samples were assessed by contemporaneous WHO methods. MAIN RESULTS AND THE ROLE OF CHANCE: Of 2085 men with cancer, 904 (43%) had haematological malignancies, 680 (33%) testicular cancers and 136 (6.5%) were adolescents. Most men (89%) and adolescents (80%) could collect sperm. Sperm output for all cancers and non-cancer diseases was lower than controls. Sperm output correlated positively with total testicular volume (r = 0.44, P < 0.0001) and negatively with serum FSH and LH (r = -0.24, -0.12, respectively, both P < 0.0001) but not testosterone. For all stored samples, the median time in cryostorage was 8.5 years, 7% were transferred for use to induce pregnancy (median time 2.5 years) and 62.2% were discarded as no longer needed (return of fertility, 35.9% median 3.5 years; death, 26.3%, median 6.5 years), the high disposal rate reflecting regular annual follow-up to establish ongoing need for continued cryostorage. Cryostorage facilities are not available in remote and rural areas of the State and the proportion of outer regional and remote area residents cryostoring sperm was only about half that compared with urban residents. LIMITATIONS, REASONS FOR CAUTION: This study does not report the pregnancy outcomes of the patients who used the cryostored sperm, due to recent limitations on health data privacy. WIDER IMPLICATIONS OF THE FINDINGS: Sperm cryostorage is feasible for virtually all men, including sufficiently mature adolescents, who can collect semen to insure future paternity as well as making positive psychological preparation for the patient's survival. Disposal of cryostored material when no longer required is efficient with regular follow-up. Sperm cryopreservation should be an integral part of comprehensive treatment plan in men receiving gonadotoxic treatment but remains underutilized. STUDY FUNDING/COMPETING INTEREST(S): There was no external funding for this study and there were no relevant conflicts of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Shankara-Narayana N, Di Pierro I, Fennell C, et al. Sperm cryopreservation prior to gonadotoxic treatment: experience of a single academic centre over 4 decades. Hum Reprod. 2019. PMID: 30951144. doi:10.1093/humrep/dez026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。